Novocure Announces National Reimbursement in Israel for Optune® in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that the State of Israel Ministry of Health has added Optune in combination with temozolomide to the Israeli medical services basket for the treatment of patients with newly diagnosed glioblastoma. The medical services basket includes the entire range of services, medications and devices that the insured public …

Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer

SHANGHAI & ST. HELIER, Jersey–(BUSINESS WIRE)–Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, and Novocure (NASDAQ: NVCR), a global oncology company with a proprietary platform technology called Tumor Treating Fields, today announced that the first patient has been enrolled in a phase 2 pilot clinical trial evaluating the safety …

Novocure to Participate in the 38th Annual J.P. Morgan Healthcare Conference

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) will participate in the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020, in San Francisco. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts. He is scheduled to present at 10 a.m. PST in the Elizabethan A/B conference …

Novocure and the AACR Announce 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program

The program includes research grants and career development awards totaling more than $2 million over the next three years ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) and the American Association for Cancer Research (AACR) announce today their 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research program. The program represents a joint effort to promote and …

Novocure and the AACR Announce 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program

The program includes research grants and career development awards totaling more than $2 million over the next three years ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) and the American Association for Cancer Research (AACR) announce today their 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research program. The program represents a joint effort to promote and …

Novocure to Participate in the Evercore ISI 2019 HealthCONx Conference

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that William Doyle, Novocure’s Executive Chairman, will participate in the Evercore ISI 2019 HealthCONx Conference on December 5, 2019, in Boston. Mr. Doyle’s presentation will begin at 12:30 p.m. EST. Mr. Doyle will also participate in one-on-one meetings with investors throughout the day. A live audio webcast …

Novocure Announces 43 Presentations on Tumor Treating Fields at 24th Annual Meeting of the Society for Neuro-Oncology

Presentations on Tumor Treating Fields cover a broad and growing range of topics, with nearly 80 percent of presentations prepared by external authors ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced 43 presentations on Tumor Treating Fields, including three oral presentations, will be featured at the 24th Annual Meeting of the Society for Neuro-Oncology (SNO) …

Novocure Reports Third Quarter 2019 Financial Results and Provides Company Update

Quarterly net revenues of $92.1 million, representing 42% growth versus the third quarter 2018 First quarter ever of positive net income with $0.02 in earnings per share Continued clinical progress with four ongoing phase 3 pivotal trials creating the potential for substantial market expansion over the next five years ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) …

Results from STELLAR Trial of Tumor Treating Fields with Chemotherapy in Malignant Pleural Mesothelioma Published in The Lancet Oncology

STELLAR trial demonstrated a promising median overall survival of 18.2 months when the NovoTTF-100L™ System was added to standard chemotherapies for the treatment of malignant pleural mesothelioma NovoTTF-100L is the first FDA-approved treatment for malignant pleural mesothelioma in over 15 years ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that results from the STELLAR trial …